医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Collaboration and License Agreement with Lilly to Discover Macrocyclic Peptide Drug Candidates

2013年12月20日 PM06:10
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc, a Tokyo-based biopharmaceutical company (PeptiDream)(TOKYO:4587), announced that they have entered into a Collaboration and License Agreement with US-based Eli Lilly and Company (Lilly)(NYSE:LLY) on 19 December 2013. Under the agreement, PeptiDream will identify macrocyclic peptides as potential drug candidates for disease targets being pursued by Lilly. PeptiDream will leverage its proprietary Peptide Discovery Platform System (PDPS) technology for translational synthesis, selection, and screening of nonstandard macrocyclic peptides, and Lilly will be responsible for any subsequent research and development as pharmaceutical candidates.

Under the terms of the Agreement, PeptiDream will receive an undisclosed upfront payment, research funding and milestone payments upon the successful achievement of certain development milestones. In addition, PeptiDream is eligible to receive royalties on future sales of products that arise from the collaboration.

We are very excited to start working with such an excellent partner in Lilly to discover and develop novel therapeutic peptides with the goal of developing high quality molecules for clinical development toward the clinic. This deal underscores the value of PeptiDream’s novel screening technology for therapeutic peptide discovery as a way to help advance patient care”, said Kiichi Kubota, Chief Executive Officer of PeptiDream.

About PeptiDream Inc.

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit www.peptidream.com

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-3468-9022 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作